We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Research and Markets Announces Addition of the Fourth Wave: A new Generation of Protein-Based Therapeutics

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Research and Markets Announces Addition of the Fourth Wave: A new Generation of Protein-Based Therapeutics "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Research and Markets has announced the addition of The Fourth Wave: A New Generation of Protein-Based Therapeutics to their offering.

Although protein-based therapeutics were seen as a risky and difficult field of endeavor, the biopharmaceutical industry's persistent pursuit of such agents created a multi-billion-dollar marketplace and a host of life-saving treatments.

Now, as first-generation drugs face patent expiry, the industry is pursuing technological and commercial opportunities that it hopes will yield the next generation of protein-based drugs, improving patient care and expanding market share.

Companies are developing technologies that will remodel recombinant protein and MAb therapeutics into next-generation drugs.

What opportunities are being pursued for improving protein therapeutics? How will next-generation drugs improve upon their predecessors?

Targeting protein therapeutics to reduce adverse side effects is an important goal and includes the creation of new classes of fusion proteins.

Which companies are developing leading-edge technologies? What other advantages do targeted therapeutics hold?

Researchers have developed techniques for conjugating MAbs to various payloads, such as adding cytotoxic agents or radioisotopes to protein-based drugs.

What are the advantages of these new protein conjugation techniques? Which companies lead the field?

Demand for protein therapeutics grows each year, but manufacturing therapeutic proteins remains expensive and time-consuming.

How are companies reducing cost and the time needed to produce recombinant proteins? Which methods are most promising?

Scope of this Report:

- Current market landscape: overview of the protein therapeutic market and key industry players.

- Current therapies: overview of the first three iterations of protein therapeutics.

- Emerging therapies: new approaches in developing next-generation protein therapeutics.

- Corporate profi les: a review of select companies developing next-generation protein therapeutics.

- Market outlook: challenges facing biotherapeutics and the biotechnology industry as a whole.

Some of the Companies Mentioned include: Abbott Laboratories, Abgenix, Ablynx, Abmaxis, Absalus, Affi body, Affi med Therapeutics, Agilent, AlgoNomics, Ambrx, Amgen, Applied Molecular, Evolution, AppTec Laboratory Services, Asahi Kasei, AstraZeneca, Bayer, Berlex, Biogen Idec, Biolex Therapeutics, Bioren, BioRexis Pharmaceutical, BioWa, Bristol-Myers Squibb, Cambridge Antibody Technologies (CAT), Cellectis, Celliance, Centocor, Chromos Molecular Systems, Chugai, CMC Biopharmaceuticals, Corixa, Crucell, Dainippon Sumitomo, DiNonA, Domantis, Dyax, Elan, Eli Lilly, Enzon Pharmaceuticals, ESBATech, EvoGenix, Gala Biotech, Genentech, Genetics Institute, Genzyme, GlaxoSmithKline, GlycArt Biotechnology, Glycofi, Glycotope, Gyros, Haptogen, ImClone Systems, Immunex, Immunogen.